All
Events
News
First Light Diagnostics Announces Peer-Reviewed Publication
Describing rapid and accurate immunoassay-based technology capable of counting single molecules using digital imaging without magnification Bedford, Massachusetts, October 25, 2018 (Newswire.com) – Bedford, Massachusetts, October 25, 2018 (Newswire) – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive, and cost-effective diagnostic tests for life-threatening infections today announced…
First Light Diagnostics Announces Funding from Biomedical Advanced Research and Development Authority (BARDA)
A contract extension representing $10.7 million over 2 years Bedford, MA – (October 11, 2018) – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive, and cost-effective diagnostic tests for life-threatening infections, announced today that BARDA has approved a $10.7 million extension of the Company’s multi-year contract…
First Light Diagnostics Develops a Novel Method for Rapidly Determining Effective Antibiotics for Treating Infections
Presenting Their Findings in a Scientific Poster Session at IDWeek BEDFORD, Mass., September 27, 2018 (Newswire.com) – First Light Diagnostics (formerly First Light Biosciences), a provider of innovative diagnostic tests for fighting life-threatening infections and combating the spread of antibiotic resistance, today announced they will be presenting a scientific poster detailing their novel MultiPath™ technology for…
First Light Diagnostics Appoints New CEO and Board Member
Bedford, Massachusetts, August 7, 2018 – First Light Diagnostics (formerly First Light Biosciences), a provider of innovative diagnostic tests for fighting life-threatening infections and combating the spread of antibiotic resistance, today announced the appointment of industry veteran David Macdonald as President, Chief Executive Officer and Board Member. As the new CEO of First Light Diagnostics,…
Meet Us at ASM Microbe in Atlanta June 7-11, 2018
First Light Diagnostics (formerly First Light Biosciences) would like you to join us in Atlanta for ASM Microbe 2018. We invite you to learn more about our latest developments in Clostridium diffcile testing and other advancements in rapid diagnostic testing where First Light aims to advance health care practices to improve detection of deadly hospital associated infections….
Join Us at ECCMID in Madrid April 21-24, 2018
First Light Diagnostics (formerly First Light Biosciences) welcomes you to join us at the 28th Annual ECCMID Congress in Madrid, April 21-24, 2018. First Light will be presenting our latest work highlighting our latest the advances in the detection of Clostridium difficile testing. CEO Don Straus will be in attendance and welcomes you to learn…
Updated IDSA/SHEA Clinical Practice Guidelines for Clostridium difficile Infection Recognizes the Importance of Toxin Testing.
The updated Clinical Practice Guidelines for Clostridium difficile from The Infectious Disease Society of America (IDSA) and the Society of Healthcare Epidemiology of America (SHEA) have been recently published in the journal Clinical Infectious Diseases. The new recommendations emphasize the importance of toxin tests in accurately identifying Clostridium difficile infection (CDI) and suggest that this type of testing is…
New Additions to First Light Management Team and Board of Directors
BEDFORD, Mass., November 2, 2017 – First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAIs) announced today two new additions to the First Light team. William Moffitt joins the First Light Diagnostics board of directors as its chairman. Mr….
First Light Biosciences Selected as a Semifinalist in the First Phase of the Antimicrobial Resistance Diagnostic Challenge
Bedford, MA (March 2017) — First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) today announced they had been selected as a semifinalist and awarded a $50,000 prize in the first phase (Step 1) of the Antimicrobial Resistance Diagnostic…
Don Straus Interviewed by BBC as Part of Antibiotic Resistance Program
Bedford, MA (October 2016) – First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) today announced their participation in a BBC interview. Speaking to the BBC, Don Straus, CEO of First Light Biosciences, discussed the challenges currently faced by hospitals as it relates…